Cargando…
去甲氧柔红霉素联合阿糖胞苷治疗初发急性髓系白血病的预后分析
OBJECTIVE: To explore outcomes in adult with de novo acute myeloid leukemia (AML) received IA10 (10 mg/m(2) d1–3 idarubicin plus cytarabine 100 mg/m(2) d1–7) regimen as induction chemotherapy. METHODS: From January 2008 to February 2016, data of consecutive newly-diagnosed AML (non-M(3)) adults trea...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343116/ https://www.ncbi.nlm.nih.gov/pubmed/29551027 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.01.004 |
Ejemplares similares
-
去甲氧柔红霉素10和8 mg/m(2)联合阿糖胞苷治疗初发急性髓系白血病的比较性研究
Publicado: (2015) -
不同剂量去甲氧柔红霉素联合阿糖胞苷诱导治疗年轻初发急性髓系白血病的疗效和安全性分析
Publicado: (2016) -
高三尖杉酯碱、阿糖胞苷、柔红霉素或去甲氧柔红霉素(HAD/HAI)诱导治疗初治急性髓系白血病的长期疗效分析
Publicado: (2016) -
含不同剂量去甲氧柔红霉素的IA方案诱导治疗成人初发急性髓系白血病的疗效和安全性研究
Publicado: (2017) -
60 mg·m(−2)·d(−1)柔红霉素联合标准剂量阿糖胞苷诱导治疗≤65岁初治急性髓系白血病患者的疗效和安全性分析
Publicado: (2016)